Alfresa Holdings Corporation
Stock Price Chart
2026/07/15 UpdatedPrice Trend
2026/07/15 UpdatedPrice & Trading Details
2026/07/15 UpdatedPRICE
TRADING
Analyst Recommendations 3 analysts
Updated 2026/05/01Earnings Calendar
Updated 2026/05/01Shareholder Composition
Updated 2026/05/01Major Holders
Updated 2026/05/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
2.4M | +12.80% | |
|
HARTFORD MUTUAL FUNDS INC/CT-The Hartford International Value Fund
|
1.6M | +17.71% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
1.5M | +15.16% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.1M | 0.00% | |
|
Fidelity Salem Street TRT-Fidelity SAI Intl Low Volatility Index Fd.
|
784.1K | +1.00% | |
|
SCHWAB STRATEGIC TRUST-Schwab Fundamental International Equity ETF
|
586.2K | +4.92% |
Dividend History
Updated 2026/07/12| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥34 | -48.5% |
| 2025 | ¥66 | -1.5% |
| 2024 | ¥67 | +6.3% |
| 2023 | ¥63 | +14.5% |
| 2022 | ¥55 | - |
Financial Performance
2026/07/12 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥2,585,643M | ¥2,696,069M | ¥2,858,500M | ¥2,961,051M |
| Gross Profit | ¥187,468M | ¥192,085M | ¥206,371M | ¥213,927M |
| Operating Income | ¥29,091M | ¥30,148M | ¥38,461M | ¥38,081M |
| Pretax Income | ¥48,253M | ¥38,655M | ¥43,927M | ¥39,638M |
| Net Income | ¥32,182M | ¥25,786M | ¥29,558M | ¥27,389M |
| EPS | ¥153.57 | ¥127.42 | ¥154.13 | - |
| Operating Margin | 1.13% | 1.12% | 1.35% | 1.29% |
| Balance Sheet | ||||
| Total Assets | ¥1,303,991M | ¥1,339,852M | ¥1,447,625M | ¥1,439,885M |
| Total Equity | ¥471,591M | ¥488,090M | ¥479,599M | ¥481,787M |
| Total Liabilities | ¥832,400M | ¥851,762M | ¥968,026M | ¥958,098M |
| Cash | ¥180,436M | ¥160,122M | ¥213,756M | ¥177,085M |
| Interest-bearing Debt | ¥5,039M | ¥3,855M | ¥34,937M | ¥35,545M |
| Equity Ratio | 36.17% | 36.43% | 33.13% | 33.46% |
| D/E Ratio | 0.01 | 0.01 | 0.07 | 0.07 |
| Cash Flow | ||||
| Operating CF | ¥36,546M | ¥13,086M | ¥86,379M | ¥5,639M |
| Investing CF | ¥2,304M | -¥20,539M | -¥14,217M | -¥24,917M |
| Financing CF | -¥29,151M | -¥12,918M | -¥19,698M | -¥23,534M |
| Free CF | ¥19,558M | -¥12,379M | ¥71,051M | -¥14,489M |
| Efficiency | ||||
| ROE | 6.82% | 5.28% | 6.16% | 5.68% |
| ROA | 2.47% | 1.92% | 2.04% | 1.90% |
Latest IR Information
-
FY March 2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)
For the third quarter of the fiscal year ending March 2026, consolidated net sales were ¥2,363,086 million (4.5% YoY increase), operating income was ¥29,731 million (4.5% YoY decrease), and net income attributable to owners of parent for the quarter was...
Read more -
Notice Regarding the Recording of Special Profit (Gain on Sales of Investment Securities)
Recorded a gain on sales of investment securities of 15,449 million yen in the third quarter of the fiscal year ending March 2026. The sale was intended to reduce policy-held shares and improve asset efficiency, with no impact on earnings...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥2,475
Rating Score: 3.00 (Based on 3 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. It is also involved in the operation of dispensing pharmacies and conducting related businesses; ethical pharmaceuticals wholesaling business; self-medication products wholesaling business; and other medical-related businesses. In addition, the company manufactures and markets active pharmaceutical ingredients; contract distribution services in hospitals; operation, maintenance, and development of information system; supply of cell raw materials; manufacturing of specific processed cells and regenerative medicine products. The company was incorporated in 2003 and is based in Tokyo, Japan.
